 |
7 Companies | 6 Products |
|
|
6 Products | |
29 Diseases | |
11 Trials |  |
763 News |  |
| «12...2223242526272829303132...134135» |
- Development of an adult rodent microglia cellular model for the characterization of NLRP3 inflammasome pathway small molecule modulators (SDCC Halls B-H) - Oct 10, 2022 - Abstract #Neuroscience2022NEUROSCIENCE_11152;
In addition, we used the selective NLRP3 small molecule inhibitor, MCC950 (Perregaux et al., 2001; Collet al., 2015), to inhibit the inflammasome response in these cell cultures. In accordance with previous data, we show that MCC950 is a selective and potent NLRP3 inhibitor, and that our adult rodent microglia cellular model can be used to further characterize NLRP3 inflammasome pathway novel modulators.
- Therapeutic effect of boldine in spare nerve injury-induced pain in mice (SDCC Halls B-H) - Oct 10, 2022 - Abstract #Neuroscience2022NEUROSCIENCE_9783;
In accordance with previous data, we show that MCC950 is a selective and potent NLRP3 inhibitor, and that our adult rodent microglia cellular model can be used to further characterize NLRP3 inflammasome pathway novel modulators. Oral administration of boldine could alleviate spare nerve injury-induced neuropathic pain, possibly through inhibiting the NLRP3 inflammasome activation.
- The role of proinflammatory multi-protein complex NLRP3 in a rat model of inherited, persistent hyperalgesia (SDCC Halls B-H) - Oct 10, 2022 - Abstract #Neuroscience2022NEUROSCIENCE_9780;
Future studies are needed to directly test the effects of ROS and TLR4 on NLRP3 activity in SS rats. The findings support the use of the SS rat as a strain to investigate how inflammation pathways contribute to conditions involving inherited chronic pain conditions.
- SARS-CoV-2 N-protein promotes neuroinflammation via microglial NLRP3 inflammasome activation (SDCC Halls B-H) - Oct 10, 2022 - Abstract #Neuroscience2022NEUROSCIENCE_9702;
The aforementioned effects associated with N-protein were significantly attenuated by either a specific NLRP3 inhibitor MCC950 or a caspase-1 inhibitor Ac-YVAD. Taken together, these results demonstrated that the N-protein of SARS-CoV-2 promoted microglial NLRP3 inflammasome activation and resultant neuroinflammatory responses, which may underlie the pathogenesis of neurological syndromes seen in patients with COVID-19.
- Pre-clinical characterization of NLRP3 inflammasome inhibitor to modulate chronic neuroinflammation and neurodegenerative pathology (SDCC Halls B-H) - Oct 10, 2022 - Abstract #Neuroscience2022NEUROSCIENCE_8391;
Taken together, these results demonstrated that the N-protein of SARS-CoV-2 promoted microglial NLRP3 inflammasome activation and resultant neuroinflammatory responses, which may underlie the pathogenesis of neurological syndromes seen in patients with COVID-19. This work provides insights into the NLRP3 inflammasome complex role in modulating neurodegeneration and neuroinflammation.
- dapansutrile (OLT1177) / Olatec Therap
Pharmacologic inhibition of NLRP3 by OLT1177 reduces the levels of α-synuclein and protects dopaminergic neurons from degeneration in a neurotoxic model of Parkinson’s disease (SDCC Halls B-H) - Oct 10, 2022 - Abstract #Neuroscience2022NEUROSCIENCE_8209;
We show that the treatment with OLT1177® 1) prevented the loss of motor function, 2) suppressed the levels of pro-inflammatory cytokines in the nigrostriatal areas of the brain, 3) reduced the amount of α-synuclein, and 4) protected dopaminergic neurons from degeneration. These data suggest that targeting the NLRP3 inflammasome by OLT1177® should be considered a novel therapeutic approach to arrest neuroinflammation and protects against neurological deficits of Parkinson’s disease in humans.
- RRx-001 / EpicentRx
The NLRP3 inhibitor RRx-001 crosses the blood brain barrier and alleviates neuroinflammation in experimental models of Parkinson’s disease (SDCC 1) - Oct 10, 2022 - Abstract #Neuroscience2022NEUROSCIENCE_1053;
Together, our data demonstrates that RRx-001 crosses the blood brain barrier and can mitigate inflammasome activation in microglia and macrophages. This highlights the neuroprotective properties of RRx-001 as a novel disease-modifying agent for PD and other neurodegenerative diseases linked to NLRP3-driven pathology.
- | Journal: C3aR contributes to unilateral ureteral obstruction-induced renal interstitial fibrosis via the activation of the NLRP3 inflammasome. (Pubmed Central) - Oct 7, 2022
This highlights the neuroprotective properties of RRx-001 as a novel disease-modifying agent for PD and other neurodegenerative diseases linked to NLRP3-driven pathology. Our data revealed that C3aR may aggravate RIF by regulating the activation of the NLRP3 inflammasome (particularly regulating inflammasome assembly) in renal tubular epithelial cells in the UUO model.
- | Journal: Reactive oxygen species-dependent-NLRP3 inflammasome activation in human neutrophils induced by l-amino acid oxidase derived from Calloselasma rhodostoma venom. (Pubmed Central) - Oct 7, 2022
IL-1β was also released, and pharmacological inhibition of NLRP3, caspase-1, and ROS reduced the amount of released cytokine. This is the first report demonstrating the activation of the NLRP3 inflammasome complex via ROS generation by Cr-LAAO, which may lead to the development of local inflammatory effects observed in snakebite victims.
- | Journal: Sennoside A is a novel inhibitor targeting caspase-1. (Pubmed Central) - Oct 6, 2022
Sen A also restrained the large pore-forming functionalities of the P2X7R as verified by the YO-PRO-1 uptake assay. Taken together, Sen A inactivates caspase-1 to inhibit NLRP3 and AIM2 inflammasome-involved inflammation in a P2X7-dependent manner, making it an attractive candidate as a caspase-1 small-molecular inhibitor.
- A Tumor-Lung NLRP3-TLR4 Distant Signaling Axis Drives Immunotherapy Resistance via G-CSF-dependent Expansion of Circulating PD1+ PMN-MDSCs (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_866;
We conclude that this tumor-lung crosstalk supports primary tumor growth and contributes to anti-PD-1 immunotherapy resistance partially by serving as an anti-PD-1 antibody sink. Pharmacologic inhibition of NLRP3 and HSP70 represents promising strategies for overcoming anti-PD-1 resistance.
- RRx-001 / EpicentRx
RRx-001, a Hypoxic No Donor and NLRP3 Inflammasome Inhibitor, in Phase 3 for the Treatment of Cancer, Cardioprotects Following Acute Myocardial Infarction (Zone 1, Science and Technology Hall, Level 3; Poster Board no. 1124) - Oct 5, 2022 - Abstract #AHA2022AHA_8091;
P3
RRx-001 increases local NO levels under hypoxia without the need for continuous intravenous infusion of NO donors and without altering systemic hemodynamics. It has the potential to improve wound healing responses and pathological remodeling and thereby attenuate the development of ischemic heart failure.
- | acetylcysteine solution / Generic mfg.
Journal: Activating α7nAChR ameliorates abdominal aortic aneurysm through inhibiting pyroptosis mediated by NLRP3 inflammasome. (Pubmed Central) - Oct 5, 2022
In vitro, N-acetylcysteine (NAC) inhibited NLRP3 inflammasome activation and NLRP3 knockdown reduced GSDMD expression, in MOVAS cells treated with TNF-α...In conclusion, our study found that activating α7nAChR retarded AAA through inhibiting pyroptosis mediated by NLRP3 inflammasome. These suggested that α7nAChR would be a potential pharmacological target for AAA.
- || Review, Journal: Inflammasome Activation in Parkinson's Disease. (Pubmed Central) - Oct 5, 2022
Converging lines of evidence suggest that blocking inflammasome activation could be a promising therapeutic strategy for disease modification, with both NLRP3 knockout mice and CNS-permeable pharmacological inhibitors providing robust neuroprotection in multiple PD models. This review summarizes the current evidence and knowledge gaps around inflammasome activation in PD, the pathological mechanisms by which persistent inflammasome activation can drive dopaminergic degeneration and the therapeutic opportunities for disease modification using NLRP3 inhibitors.
- | Journal: Isobavachalcone's Alleviation of Pyroptosis Contributes to Enhanced Apoptosis in Glioblastoma: Possible Involvement of NLRP3. (Pubmed Central) - Oct 5, 2022
IBC's inhibition on NLRP3 could be rescued by the NLRP3 antagonist CY-09 both in vitro and in vivo. These results indicate that IBC is a potential therapeutic drug against GBM and provide a new insight into GBM treatment.
- | pioglitazone / Generic mfg.
Preclinical, Journal: Pioglitazone Protects Against Hypoxia-Induced Cardiomyocyte Apoptosis Through Inhibiting NLRP3/Caspase-1 Pathway in vivo and in vitro. (Pubmed Central) - Oct 5, 2022
Additionally, we confirmed that Pio pretreatment inhibited cardiomyocyte apoptosis via repressing the NLRP3/caspase-1 pathway. In conclusion, our study demonstrated that Pio could inhibit myocardial I/R injury and cardiomyocyte apoptosis by inhibiting the activation of the NLRP3/caspase-1 signaling pathway.
- | Journal: Water-extracted Lonicera japonica polysaccharide attenuates allergic rhinitis by regulating NLRP3-IL-17 signaling axis. (Pubmed Central) - Oct 4, 2022
In vitro interaction analysis showed a significant interaction between CY-09 and WLJP. In conclusion, WLJP improves AR by repairing the gut barrier and inhibiting NLRP3 inflammasome-driven inflammation and the Th17 immune response.
- || Review, Journal: The Role of Inflammasome NLPR3 in the Development and Therapy of Periodontitis. (Pubmed Central) - Oct 4, 2022
Then we elucidate the development status of NLRP3 inflammasome inhibitors and show their application potential for treating periodontitis. In summary, this review reveals the recent progress and perspectives of NLRP3 inflammasome and the therapeutic potential of NLRP3 inflammasome inhibitors in periodontitis.
- | belnacasan (VX-765) / Vertex
Preclinical, Journal: Kir6.1/K-ATP channel in astrocytes is an essential negative modulator of astrocytic pyroptosis in mouse model of depression. (Pubmed Central) - Oct 4, 2022
More importantly, VX-765, an effective and selective inhibitor for NLRP3 inflammasome, could reverse the astrocytic pyroptosis and rescue the deterioration of behaviors in astrocytic Kir6.1 knockout mice. Our findings illustrate that Kir6.1/K-ATP channel in astrocytes is an essential negative modulator of astrocytic pyroptosis and plays a crucial role in depression and suggest that astrocytic Kir6.1/K-ATP channel may be a promising therapeutic target for depression.
- | Journal: LncRNA MDRL Mitigates Atherosclerosis through miR-361/SQSTM1/NLRP3 Signaling. (Pubmed Central) - Oct 4, 2022
In summary, MDRL alleviates NLRP3 inflammasome activation and apoptosis in VSMCs through miR-361/SQSTM1/NLRP3 pathway during atherogenesis. These data indicate that MDRL and inhibition of miR-361 represent potential therapeutic targets in atherosclerosis-related diseases.
- | Preclinical, Journal: Increased core body temperature exacerbates defective protein prenylation in mouse models of mevalonate kinase deficiency. (Pubmed Central) - Oct 4, 2022
Importantly, these mice allowed the determination of a threshold level of residual enzyme activity, below which protein prenylation is impaired. Elevated temperature dramatically but reversibly exacerbated the deficit in the mevalonate pathway and the defective prenylation in vitro and in vivo, highlighting increased body temperature as a likely trigger of inflammatory flares.
- | Journal: NLRP3-inflammasome activation in male reproductive system diseases. (Pubmed Central) - Oct 1, 2022
The objective of this review was to analyze the evidence on the role and the mechanisms by which NLRP3-inflammasome pathway activation may exert detrimental effects on the male reproductive system. Furthermore, although the literature data are still discordant, this review also highlighted the possible connection between SARS-CoV-2 infection/NLRP3 activation/oxidative stress and male infertility.
- | Preclinical, Journal: Melatonin Attenuates Spinal Cord Injury in Mice by Activating the Nrf2/ARE Signaling Pathway to Inhibit the NLRP3 Inflammasome. (Pubmed Central) - Oct 1, 2022
Furthermore, although the literature data are still discordant, this review also highlighted the possible connection between SARS-CoV-2 infection/NLRP3 activation/oxidative stress and male infertility. In conclusion, melatonin inhibits the NLRP3 inflammasome through stimulation of the Nrf2/ARE pathway, thereby suppressing neuroinflammation, reducing mitochondrial dysfunction, and improving the recovery of nerve function after SCI.
- | atorvastatin / Generic mfg.
Journal: Integrated pyroptosis measurement and metabolomics to elucidate the effect and mechanism of tangzhiqing on atherosclerosis. (Pubmed Central) - Oct 1, 2022
After 6 weeks of atorvastatin (Ator) or TZQ treatment, aortic lumen diameter, aortic lesion size, serum lipid profile, cytokines, and Nod-like receptor protein 3 (NLRP3) inflammasome-mediated pyroptosis were analyzed...According to metabolomics profiling, TZQ is engaged in the treatment of AS via altering arachidonic acid metabolism, glycerophospholipid metabolism, steroid hormone production, and unsaturated fatty acid biosynthesis. The cytochrome P450 enzyme family and cyclooxygenase 2 (COX-2) are two major metabolic enzymes associated with pyroptosis.
- | Journal: FOSL2 deficiency delays nonalcoholic steatohepatitis progression by regulating LY6D-mediated NLRP3 activation. (Pubmed Central) - Sep 30, 2022
Moreover, the promotion of hepatocyte pyroptosis by the FOSL2/LY6D axis was significantly attenuated by specific inhibition of NLRP3. These findings suggesting that FOSL2/LY6D axis may be a key molecular axis and a potential target for NASH therapeutics.
- | Journal: miR-15b-5p regulates the NLRP3 inflammasome signal through targeting SIRT3 to regulate hypoxia/reoxygenation-induced cardiomyocyte pyroptosis process. (Pubmed Central) - Sep 30, 2022
We then utilized a rat AMI model to analyze myocardial infarction area by TTC staining and assess serum cardiac troponin T (cTnT) level by ELISA and found that miR-15b-5p silencing reduced AMI injury in rats. Collectively, these results suggest miR-15b-5p increase H/R-induced pyroptosis in cardiomyocytes by targeting SIRT3 and activating the NLRP3 inflammasome.
- | Preclinical, Journal: Preventive Effects of l-Glutamine on High-Fat Diet-Induced Metabolic Disorders Linking with Regulation of Intestinal Barrier Integrity, Hepatic Lipid Metabolism, and Gut Microbiota in Rats. (Pubmed Central) - Sep 30, 2022
Moreover, Gln administration restored HFD-induced intestinal barrier dysfunction, promoted intestinal fat absorption, suppressed intestinal inflammation, and also reshaped the gut microbiota composition in HFD-fed rats by downregulating the abundance of potential pathogens Escherichia-Shigella and upregulating the abundance of beneficial bacteria such as Akkermansia. To conclude, the present results showed that Gln may be a potential option for preventing HFD-induced metabolic disorders via the gut-liver axis.
- | Journal: The selective NLRP3-inflammasome inhibitor CY-09 ameliorates kidney injury in diabetic nephropathy by inhibiting NLRP3 inflammasome activation. (Pubmed Central) - Sep 30, 2022
To conclude, the present results showed that Gln may be a potential option for preventing HFD-induced metabolic disorders via the gut-liver axis. CY-09 effectively protects the kidney from hyperglycemia induced damage by inhibiting the NLRP3 inflammasome and may be a promising therapeutic strategy to prevent the progression of DKD.
- || Review, Journal: Pharmacological effects of Chinese medicine modulating NLRP3 inflammasomes in fatty liver treatment. (Pubmed Central) - Sep 29, 2022
Here, we summarized the mechanism of NLRP3 inflammasomes in the progression of FLD, and TCM exerts beneficial effects on FLD via positive modulation of inflammation. We describe that TCM is a promising valuable resource for the prevention and treatment agents against FLD and has the potential to be developed into clinical drugs.
- | Preclinical, Journal: DI-3-n-butylphthalide mitigates stress-induced cognitive deficits in mice through inhibition of NLRP3-Mediated neuroinflammation. (Pubmed Central) - Sep 29, 2022
And these changes induced by chronic stress could not be found in NLRP3 KO mice. These results show an important role for the NLRP3/caspase-1/IL-1β axis in chronic stress-induced cognitive deficits and NBP meliorates cognitive impairments and selectively attenuates phosphorylated tau accumulation in stressed mice through regulation of NLRP3 inflammatory signaling pathway.
- | Journal: Citrulline protects against LPS‑induced acute lung injury by inhibiting ROS/NLRP3‑dependent pyroptosis and apoptosis via the Nrf2 signaling pathway. (Pubmed Central) - Sep 29, 2022
Furthermore, the Nrf2 inhibitor ML385 reversed ROS generation, NLRP3 inflammasome-mediated pyroptosis and apoptosis suppressed by citrulline. In summary, the present data demonstrated that citrulline may confer protection against ALI via inhibition of ROS/NLRP3 inflammasome-dependent pyroptosis and apoptosis via the Nrf2 signaling pathway.
- | glibenclamide / Generic mfg.
Preclinical, Journal: Characterization of IMG Microglial Cell Line as a Valuable In Vitro Tool for NLRP3 Inflammasome Studies. (Pubmed Central) - Sep 29, 2022
We also demonstrated that treatment with NLRP3 inflammasome inhibitor glibenclamide suppressed NLRP3 inflammasome activation in IMG cells, as illustrated by the downregulation of gasdermin D N-fragment and mature caspase-1 and IL-1β protein levels...In IMG cells, 4-h incubation with lipopolysaccharide (LPS) induces a stronger upregulation of NLRP3 inflammasome-associated pro-inflammatory genes compared to 24-h incubation. NLRP3 inflammasome is robustly activated only after the addition of 3 mM of ATP following short LPS incubation time.
- | Journal: Comparative Analysis of the Metabolites and Biological Activity of Cultivated and Wild Lignosus rhinocerotis. (Pubmed Central) - Sep 29, 2022
The PLRW may alleviate lung damage by inhibiting the NLRP3 pathway and thereby suppressing the inflammatory response. In summary, both cultivated and wild L. rhinocerotis are abundant in bioactive components and have antioxidant and anti-inflammatory activities.
- | Journal: New polymerized sesquiterpene lactones from Ainsliaea yunnanensis and their activity evaluation. (Pubmed Central) - Sep 29, 2022
(CPCC 400307), Fusarium solani (CPCC 800013) or Bacillus subtilis. Meanwhile, compounds 6 and 7 can inhibit the NLRP3 inflammasome's activation at the concentration of 10 μM.
- | Journal: RNA adenosine deaminase (ADAR1) alleviates high-fat diet-induced nonalcoholic fatty liver disease by inhibiting NLRP3 inflammasome. (Pubmed Central) - Sep 29, 2022
Furthermore, we speculated that c-Jun may participate in ADAR1's inhibition of NLRP3 inflammasome. Our results suggested that ADAR1 is a potential treatment target for NAFLD via regulating the activation of NLRP3 inflammasome.
- | Journal: Mechanisms of NLRP3 activation and pathology during neurodegeneration. (Pubmed Central) - Sep 29, 2022
Therapeutic strategies around inhibition of NLRP3 activation in the central nervous system are already being evaluated to determine their effectiveness to slow progressive neurodegeneration. This review summarizes current understanding of inflammasomes in the most prevalent neurodegenerative diseases and discusses current knowledge gaps and inflammasome inhibition as a therapeutic strategy.
- | Journal: Effects of mitochondrial reactive oxygen species-induced NLRP3 inflammasome activation on trichloroethylene-mediated kidney immune injury. (Pubmed Central) - Sep 29, 2022
The in vitro studies proved that C5b-9 can induce mtROS release and activate the assembly of NLRP3 inflammasome in HK-2 cells. In conclusion, in TCE-sensitized positive mouse renal tubular epithelial cells, C5b-9 caused calcium influx and thus induced mitochondrial injury and mtROS overexpression, finally inducing MAVS expression and NLRP3 inflammasome activation and kidney injury.
- | ibuprofen / Generic mfg.
Preclinical, Journal: Prim-O-glucosycimifugin attenuates liver injury in septic mice by inhibiting NLRP3 inflammasome/caspase-1 signaling cascades in macrophages. (Pubmed Central) - Sep 29, 2022
In conclusion, in TCE-sensitized positive mouse renal tubular epithelial cells, C5b-9 caused calcium influx and thus induced mitochondrial injury and mtROS overexpression, finally inducing MAVS expression and NLRP3 inflammasome activation and kidney injury. POG protected against sepsis by inhibiting NLRP3 inflammasome-mediated macrophage activation in septic liver and attenuating liver inflammatory injury, indicating that it may be a potential anti-sepsis drug candidate.
- | Journal: Irisin inhibits NLRP3 inflammasome activation in HG/HF incubated cardiac microvascular endothelial cells with H/R injury. (Pubmed Central) - Sep 25, 2022
POG protected against sepsis by inhibiting NLRP3 inflammasome-mediated macrophage activation in septic liver and attenuating liver inflammatory injury, indicating that it may be a potential anti-sepsis drug candidate. The current study demonstrated for the first time that irisin inhibits NLRP3 inflammasome activation in CMECs as a novel mechanism in myocardial ischemia/reperfusion injury in diabetes.
- | Journal: Zinc Promotes Spinal Cord Injury Recovery by Blocking the Activation of NLRP3 Inflammasome Through SIRT3-Mediated Autophagy. (Pubmed Central) - Sep 25, 2022
These findings suggest that zinc improves neuroinflammation and improves dyskinesia after SCI. In conclusion, zinc may be a potential therapeutic immunomodulatory challenge for the treatment of trauma-related CNS dysfunction.
- | Preclinical, Journal: Hydrogen Sulfide Attenuates Neuroinflammation by Inhibiting the NLRP3/Caspase-1/GSDMD Pathway in Retina or Brain Neuron following Rat Ischemia/Reperfusion. (Pubmed Central) - Sep 25, 2022
This is supported by the fact that it reversed the high-level of NLRP3, caspase-1, and GSDMD following I/R. Our findings suggest that compounds with the ability to donate HS could constitute a novel therapeutic strategy for ischemic stroke.
- | Journal: Itaconate Attenuates Neuroinflammation and Exerts Dopamine Neuroprotection in Parkinson's Disease through Inhibiting NLRP3 Inflammasome. (Pubmed Central) - Sep 25, 2022
Additionally, itaconate notably repressed the activation of NLRP3 inflammasome. This research demonstrated that itaconate could attenuate neuroinflammation and exert dopamine neuroprotection in PD through inhibiting NLRP3 inflammasome.
- | Journal: Discovery of a Novel Oral Proteasome Inhibitor to Block NLRP3 Inflammasome Activation with Anti-inflammation Activity. (Pubmed Central) - Sep 24, 2022
Importantly, NIC-0102 showed potent anti-inflammatory effects on DSS-induced ulcerative colitis model in vivo. As a result of these studies, a potential small molecule is identified to demonstrate the possible link between the proteasome and NLRP3 pathway, which supports further exploration of potentially druggable nodes to modulate NLRP3 inflammasome activation.
- | Journal: HO-1/autophagic flux axis alleviated sepsis-induced acute lung injury via inhibiting NLRP3 inflammasome. (Pubmed Central) - Sep 24, 2022
Autophagic flux activator could suppress NLRP3 inflammasome activation and attenuate ALI, while autophagic flux inhibitor had the opposite effect. In conclusion, our study revealed increased HO-1 expression inhibited the level of NLRP3 inflammasome via regulating the activation of autophagic flux, thus attenuating inflammatory response and alleviating sepsis-induced ALI.
- | Journal: Pentraxin-3 promotes LPS-induced pyroptosis in human periodontal ligament stem cells. (Pubmed Central) - Sep 23, 2022
Inhibition of NLRP3 inflammasome and/or caspase-1 partially attenuated the effects of PTX3 on LPS-stimulated hPDLSCs. This study indicated that PTX3 promotes LPS-induced pyroptosis and inflammation in hPDLSCs through activation of the caspase-1-dependent NLRP3 inflammasome.
- | Journal: P2X7R-NEK7-NLRP3 Inflammasome Activation: A Novel Therapeutic Pathway of Qishen Granule in the Treatment of Acute Myocardial Ischemia. (Pubmed Central) - Sep 22, 2022
In addition, inhibition or overexpression of P2X7R in RAW264.7 macrophages and immunoprecipitated protein interactions further confirmed that QSG reduces macrophages inflammasome activation via the P2X7R-NEK7-NLRP3 pathway. P2X7R-NEK7-NLRP3 inflammasome activation is a novel therapeutic mechanism of QSG in the treatment of acute myocardial ischemia.
- SCFAs participate in the pathogenesis of Parkinson’s disease by regulating NLRP3 inflammasomes activation (Poster Station: 25) - Sep 22, 2022 - Abstract #MDSCongress2022MDR_Congress_1519;
P2X7R-NEK7-NLRP3 inflammasome activation is a novel therapeutic mechanism of QSG in the treatment of acute myocardial ischemia. SCFAs participate in the pathogenesis of PD by regulating NLRP3 inflammasomes activation through GPR43.
- | Preclinical, Journal: A novel nutritional mixture, MBN, prevents memory impairment via inhibiting NLRP3 inflammasome formation in 5xFAD transgenic mice. (Pubmed Central) - Sep 21, 2022
Taken together, our findings demonstrate that MBN suppresses neuroinflammation by downregulating the caspase-1 expression, thereby ameliorating memory impairment in 5xFAD mice. Based on these results, we suggest that MBN may be a preventive and therapeutic supplement for AD through the regulation of neuroinflammation.
- | allopurinol / Generic mfg.
Journal: Therapeutic effects and mechanisms of N-(9,10-anthraquinone-2-ylcarbonyl) xanthine oxidase inhibitors on hyperuricemia. (Pubmed Central) - Sep 21, 2022
After treatment with different doses of NAY (low dose: 10 mg/kg, medium dose: 20 mg/kg, and high dose: 40 mg/kg) and allopurinol (positive drug, 10 mg/kg), observe the levels of uric acid (UA), creatinine (CRE), and urea nitrogen (BUN) in urine and serum, respectively, and detect the activities of xanthine oxidase in the liver...On the one hand, it can inhibit the formation of UA by inhibiting xanthine oxidase inhibitors activity, and on the other hand, it can promote the excretion of UA by regulating the UA transporter. It provides new ideas for the development of hyperuricemia drugs in the future.
- | Journal: Loganin Prevents Hepatic Steatosis by Blocking NLRP3 Inflammasome Activation. (Pubmed Central) - Sep 20, 2022
Our findings indicate that loganin alleviates the inflammatory symptoms associated with NASH, presumably by inhibiting NLRP3 inflammasome activation. In summary, these findings imply that loganin may be a novel nutritional and therapeutic treatment for NASH-related inflammation.